Evolutionary clade affects resistance of Clostridium difficile spores to Cold Atmospheric Plasma

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Connor, Mairéad ^a   Flynn, Padrig B ^a   Fairley, Derek J ^b   Marks, Nikki ^a   Manesiotis, Panagiotis ^a   Graham, William G ^a   Gilmore, Brendan F ^a   McGrath, John W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISINFECTANT AGENT; HYDROGEN PEROXIDE; OXYGEN;

ANTIBIOTIC RESISTANCE; BACTERIAL SPORE; DECONTAMINATION; DRUG EFFECT; ENVIRONMENT; GENETICS; METABOLISM; MICROBIAL VIABILITY; MOLECULAR EVOLUTION; PEPTOCLOSTRIDIUM DIFFICILE; PH; PHARMACOLOGY; PHYSIOLOGY; PLASMA GAS; PROCEDURES; TIME FACTOR;

CLOSTRIDIUM DIFFICILE; DECONTAMINATION; DISINFECTANTS; DRUG RESISTANCE, BACTERIAL; ENVIRONMENT; EVOLUTION, MOLECULAR; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; MICROBIAL VIABILITY; OXYGEN; PLASMA GASES; SPORES, BACTERIAL; TIME FACTORS;

EID: 85011545349     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41814     Document Type: Article

References (52)

1. Fordtran, J. S. Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc. (Bayl. Univ. Med. Cent). 19, 3-12 (2006).
2. Rodriguez-Palacios, A. & LeJeune, J. T. Moist-heat resistance, spore aging, and superdormancy in Clostridium difficile. Appl. Environ. Microbiol. 77, 3085-3091 (2011).
3. Fawley, W. N. et al. Efficacy of Hospital Cleaning Agents and Germicides Against Epidemic Clostridium difficile Strains o. Infect. Control Hosp. Epidemiol. 28, 920-925 (2007).
4. Perry, C., Marshall, R. & Jones, E. Bacterial contamination of uniforms. J. Hosp. Infect. 48, 238-241 (2001).
5. Vindigni, S. M. & Surawicz, C. M. Clostridium difficile Infection: Changing Epidemiology and Management Paradigms. Clin. Transl. Gastroenterol. 6, e99 (2015).
6. Kyne, L., Hamel, M. B., Polavaram, R. & Kelly, C. P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34, 346-353 (2002).
7. Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E. & Silva, J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp ⋯ 16, 459-477 (1995).
8. The National Institute for Health and Care Excellence. Clostridium difficile infection: risk with broad-spectrum antibiotics | Keypoints-from-the-evidence | Advice | NICE (2015).
9. Bignardi, G. E. Risk factors for Clostridium difficile infection. J. Hosp. Infect. 40, 1-15 (1998).
10. Siegel, J. D., Rhinehart, E., Jackson, M. & Chiarello, L. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am. J. Infect. Control 35 (2007).
11. Rupnik, M. Clostridium difficile: (Re)emergence of Zoonotic Potential. Clin. Infect. Dis. 51, 583-584 (2010).
12. Wilcox, M. H. et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotypingbased surveillance scheme in England. Clin. Infect. Dis. 55, 1056-1063 (2012).
13. Dingle, K. E. et al. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol. Evol. 6, 36-52 (2014).
14. Griffiths, D. et al. Multilocus sequence typing of Clostridium difficile. J. Clin. Microbiol. 48, 770-778 (2010).
15. Fairley, D. J. et al. Association of Clostridium difficile ribotype 078 with detectable toxin in human stool specimens. J. Med. Microbiol. 64, 1341-1345 (2015).
16. Abreu, A. C., Tavares, R. R., Borges, A., Mergulhão, F. & Simões, M. Current and emergent strategies for disinfection of hospital environments. J. Antimicrob. Chemother. 68, 2718-2732 (2013).
17. Speight, S. et al. Evaluation of the sporicidal activity of different chemical disinfectants used in hospitals against Clostridium difficile. J. Hosp. Infect. 79, 18-22 (2011).
18. Vonberg, R. P. et al. Infection control measures to limit the spread of Clostridium difficile. Clin. Microbiol. Infect. 14, 2-20 (2008).
19. Department of Health and HPA. Clostridium difficile infection: How to deal with the problem. 140 (2008).
20. Health and Safety Executive. EH4O/2005 Workplace exposure limits EH4O/2005 Workplace exposure limits. Eh40/2005 1-74 (2011).
21. Goldenberg, S. D., Patel, A., Tucker, D. & French, G. L. Lack of enhanced effect of a chlorine dioxide-based cleaning regimen on environmental contamination with Clostridium difficile spores. J. Hosp. Infect. 82, 64-67 (2012).
22. Davies, A., Pottage, T., Bennett, A. & Walker, J. Gaseous and air decontamination technologies for Clostridium difficile in the healthcare environment. J. Hosp. Infect. 77, 199-203 (2011).
23. Grass, G., Rensing, C. & Solioz, M. Metallic copper as an antimicrobial surface. Appl. Environ. Microbiol. 77, 1541-1547 (2011).
24. Wheeldon, L. J. et al. Antimicrobial efficacy of copper surfaces against spores and vegetative cells of Clostridium difficile: The germination theory. J. Antimicrob. Chemother. 62, 522-525 (2008).
25. von Woedtke, T., Metelmann, H.-R. & Weltmann, K.-D. Clinical Plasma Medicine: State and Perspectives of in vivo Application of Cold Atmospheric Plasma. Contrib. to Plasma Phys. 54, 104-117 (2014).
26. Laroussi, M. Low Temperature Plasma-Based Sterilization: Overview and State-of-the-Art. Plasma Process. Polym. 2, 391-400 (2005).
27. Flynn, P. B. et al. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens. Int J Antimicrob Agents 46(1), 101-7 (2015).
28. Alkawareek, M. Y. et al. Eradication of Pseudomonas aeruginosa biofilms by atmospheric pressure non-thermal plasma. PLoS One 7, e44289 (2012).
29. Tavares, M. B. et al. Bacillus subtilis endospores at high purity and recovery yields: Optimization of growth conditions and purification method. Curr. Microbiol. 66, 279-285 (2013).
30. Klämpfl, T. G. et al. Decontamination of Nosocomial Bacteria Including Clostridium difficile Spores on Dry Inanimate Surface by Cold Atmospheric Plasma. Plasma Process. Polym. 11, 974-984 (2014).
31. Claro, T., Cahill, O. J., O'Connor, N., Daniels, S. & Humphreys, H. Cold-Air Atmospheric Pressure Plasma Against Clostridium difficile Spores: A Potential Alternative for the Decontamination of Hospital Inanimate Surfaces. Infect. Control Hosp. Epidemiol. 36, 742-4 (2015).
32. Tseng, S., Abramzon, N., Jackson, J. O. & Lin, W. J. Gas discharge plasmas are effective in inactivating Bacillus and Clostridium spores. Appl. Microbiol. Biotechnol. 93, 2563-2570 (2012).
33. Galvin, S. et al. The antimicrobial effects of helium and helium-air plasma on Staphylococcus aureus and Clostridium difficile. Lett. Appl. Microbiol. 57, 83-90 (2013).
34. Hong, Y. F. et al. Sterilization effect of atmospheric plasma on Escherichia coli and Bacillus subtilis endospores. Lett. Appl. Microbiol. 48, 33-7 (2009).
35. Sharma, A., Pruden, A., Stan, O. & Collins, G. J. Bacterial Inactivation Using an RF-Powered Atmospheric Pressure Plasma. IEEE Trans. Plasma Sci. 34, 1290-1296 (2006).
36. Walker, A. S. et al. Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile Infection. 56, (2013).
37. Merrigan, M. et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J. Bacteriol. 192, 4904-4911 (2010).
38. Vohra, P. & Poxton, I. R. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology 157, 1343-1353 (2011).
39. He, M. et al. Europe PMC Funders Group Emergence and global spread of epidemic healthcare-associated Clostridium difficile. 45, 109-113 (2012).
40. Aitken, S. L. et al. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect. Control Hosp. Epidemiol. 36, 1-6 (2015).
41. Paredes-Sabja, D., Shen, A. & Sorg, J. A. Clostridium difficile spore biology: Sporulation, germination, and spore structural proteins. Trends Microbiol. 22, 406-416 (2014).
42. Lewis, D. L. & Arens, M. Resistance of microorganisms to disinfection in dental and medical devices. Nat. Med. 1, 956-958 (1995).
43. Sun, P. et al. Inactivation of Bacillus subtilis spores in water by a direct-current, cold atmospheric-pressure air plasma microjet. Plasma Process. Polym. 9, 157-164 (2012).
44. Alshraiedeh, N. H. et al. Eradication and phenotypic tolerance of Burkholderia cenocepacia biofilms exposed to atmospheric pressure non-thermal plasma. Int. J. Antimicrob. Agents 47, 446-450 (2016).
45. Lademann, J. et al. Risk assessment of the application of tissue-tolerable plasma on human skin. Clin. Plasma Med. 1, 5-10 (2013).
46. Weltmann, K. D. et al. Atmospheric pressure plasma jet for medical therapy: Plasma parameters and risk estimation. Contrib. to Plasma Phys. 49, 631-640 (2009).
47. Banerjee, S. et al. Infection control during GI endoscopy. Gastrointest. Endosc. 67, 781-790 (2008).
48. UK Standards for Microbiology Investigations. UK Standards for Microbiology Investigations: Processing of Faeces for Clostridium difficile. 1-23 (2014).
49. Sousa, J. S. et al. Cold atmospheric pressure plasma jets as sources of singlet delta oxygen for biomedical applications. J. Appl. Phys. 109, (2011).
50. Algwari, Q. T. & O'Connell, D. Electron dynamics and plasma jet formation in a helium atmospheric pressure dielectric barrier discharge jet. Appl. Phys. Lett. 99, 121501 (2011).
51. 2. Plasma Sources Sci. Technol. 23, 015019 (2014).
52. Eisenberg, G. Colorimetric Determination of Hydrogen Peroxide. Ind. Eng. Chem. Anal. Ed. 15, 327-328 (1943).